SEC For	rm 4 FORM	4	UNITE	) ST/	ATES S	ECURITIE	SAN	DE	ХСНА	NG	E CC	OMMI	SSION					
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).			Washington, D.C. 20549												OMB APPROVAL			
			STATEMENT OF CHANGES IN BENEFICIAL OWNE Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										HIP	Estim	OMB Number: 3 Estimated average burden hours per response:			
1. Name and Address of Reporting Perso MILANO VINCENT					BIOC	2. Issuer Name and Ticker or Trading Symbol BIOCRYST PHARMACEUTICALS INC BCRX ]								of Reportir cable) or			suer wner	
(Last) 4505 EN	(Last) (First) 4505 EMPEROR BLVD.				- 3. Date	3. Date of Earliest Transaction (Month/Day/Year) 06/12/2024							Officer below)	(give title		Other (: below)	pecify	
SUITE 2			4. If Ame	<ul> <li>4. If Amendment, Date of Original Filed (Month/Day/Year)</li> <li>6. Individual or Joint/Group Filing (Check Line)</li> <li>Form filed by One Reporting Peters</li> </ul>														
(Street) DURHAM NC			27703			Form filed b Person									by More than One Reporting			
(City)	(City) (State) (Zip)					Rule 10b5-1(c) Transaction Indication         Image: Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	ole I - Nor	1-Deri	vative Se	curities Ac	quired,	Disp	posed c	of, oi	r Bene	eficially	y Owned					
1. Title of Security (Instr. 3)			2. Transacti Date (Month/Day			Execution Date,		3. Transaction Code (Instr. 8)		4. Securities Acquired (A Disposed Of (D) (Instr. 3, 5)					Form (D) or	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	v	Amount		(A) or (D)	Price	Transact (Instr. 3 a	ion(s)				
Common Stock 06/12					2/2024		Α		6,820	(1)	Α	\$ <mark>0</mark>	\$0 74,687			D		
						urities Acqu s, warrants				·			Owned					
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution urity or Exercise (Month/Day/Year) if any			Date, Transaction Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr	6. Date Exercisable and Expiration Date (Month/Day/Year) (Instr. 3 and 4			s ecurity	8. Price of Derivative Security (Instr. 5) Beneficia Owned Following Reported Transacti		e s illy g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia Ownersh (Instr. 4)			

3, 4 and 5) (Instr. 4) Amount or Number (D) Date Exercisable Expiration Date of Shares Code ٧ (A) Title Automatic Stock Common Stock 06/12/2024 06/12/2025 \$<mark>6.3</mark> A 49,933 06/12/2034 49,933 \$<mark>0</mark> 49,933 D Option Grant<sup>(2)</sup>

Explanation of Responses:

1. Automatic non-employee director grant of Restricted Stock Units pursuant to the BioCryst Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, as amended (the "Director Compensation Policy"), which will vest on the first anniversary of the date of grant.

2. Automatic non-employee director grant of stock options pursuant to the Director Compensation Policy.

/s/ Alane P. Barnes, by power

of attorney

06/14/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.